AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial
logo

CDTX(Quitar la ciudad)

Cidara Therapeutics·NASDAQ
--
--(--)
6.47 / 10
Superar

Capital flow assessment yields 7.49/10, denoting robust fund flow characteristics. Strengths in overall, block, Small, and Extra-large trends confront pressures from Medium and Large patterns, resulting in positive liquidity outlook. Analyst sentiment reflects cautiously optimistic analyst perspective with balanced view. The rating profile includes Strong Buy(20.0%), Buy(20.0%), Neutral(60.0%) from 5 analytical reports, supported by 5.46 historical weighted rating.

FundamentalSentimiento(6.47)Técnico
Calificación de flujo de fondos
Calificación del analistaCompra fuerte

Opiniones de Wall Street

Compra fuerte

Compra fuerte

20%

Comprar

20%

Sostener

0%

Vender

0%

Venta fuerte

0%

Fecha2025-11-07
InstituciónRBC Capital
Tiempos previstos2
Tasa histórica de ganancias100.0%